🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "huge turning point" in the fight against increasingly resistant strains of the bacteria, according to scientists.

A Worldwide Public Health Issue

The sexually transmitted infection are increasing worldwide, with estimates suggesting more than 82 million instances per year. Notably increased rates are seen in Africa and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary advancement in the reality of rising global incidence, increasing antimicrobial resistance and the very limited treatment choices presently on offer.”

Health officials are particularly alarmed about the rise in antibiotic-resistant strains. The World Health Organization has listed it as a "high-priority threat". A tracking program showed that the effectiveness of primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Therapies Gain Approval

One new antibiotic, alternatively called a brand name, was authorized by the American regulatory agency in mid-December for use against gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers anticipate that specific application of this new drug will help delay the development of resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, also received approval in close succession. This drug, which is employed against urinary tract infections, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to develop it.

“This approval marks a huge turning point in the therapy of superbug gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Testing Results and Worldwide Availability

According to results detailed in a prominent scientific publication, the new drug eradicated more than 90% of genital gonorrhoea infections. This establishes an equal footing with the existing first-line therapy, which involves a dual-drug approach. The research included hundreds of volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the rights to license and sell the drug in many low-income and middle-income countries.

Medical professionals directly involved have expressed optimism. The availability of a easy-to-administer therapy such as this is hailed as a "critical tool" for managing the epidemic. This is considered vital to lessen the impact of the infection for individuals and to stop the proliferation of untreatable gonorrhoea worldwide.